TY - JOUR
T1 - Targeting the endocannabinoid system
T2 - a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
AU - Reddy, Vamsi
AU - Grogan, Dayton
AU - Ahluwalia, Meenakshi
AU - Salles, Évila Lopes
AU - Ahluwalia, Pankaj
AU - Khodadadi, Hesam
AU - Alverson, Katelyn
AU - Nguyen, Andy
AU - Raju, Srikrishnan P.
AU - Gaur, Pankaj
AU - Braun, Molly
AU - Vale, Fernando L.
AU - Costigliola, Vincenzo
AU - Dhandapani, Krishnan
AU - Baban, Babak
AU - Vaibhav, Kumar
N1 - Funding Information:
Financial support for this study was provided by grants from the National Institutes of Neurological Diseases and Stroke (NS065172, NS097825 to KMD and NS110378 to BB/KMD), National Institutes of Child Health and Development (HD094606 to KV), and American Heart Association (GRNT33700286 to KMD). Acknowledgments
Publisher Copyright:
© 2020, European Association for Predictive, Preventive and Personalised Medicine (EPMA).
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. Therefore, it is plausible to weigh carefully the beneficial effects of cannabinoids against the potential adverse impacts for every individual. This is where the concept of “personalized medicine” as a promising approach for disease prediction and prevention may take into the account. The goal of this review is to provide an outline of the endocannabinoid system, including endocannabinoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders.
AB - Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. Therefore, it is plausible to weigh carefully the beneficial effects of cannabinoids against the potential adverse impacts for every individual. This is where the concept of “personalized medicine” as a promising approach for disease prediction and prevention may take into the account. The goal of this review is to provide an outline of the endocannabinoid system, including endocannabinoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders.
KW - 2-Arachidonyl glycerol
KW - Alzheimer’s disease
KW - Amyloid lateral sclerosis
KW - Anandamide
KW - Anxiety
KW - Cancer
KW - Cannabinoid receptor
KW - Depression
KW - Disease management
KW - Endocannabinoid system
KW - Epilepsy
KW - Health policy
KW - Huntington’s disease
KW - Multi-professional expertise
KW - Multiple sclerosis
KW - Neurological disorder
KW - Pain
KW - Parkinson’s disease
KW - Predictive preventive personalized medicine (PPPM)
KW - Schizophrenia
KW - Stroke
KW - Therapeutic strategies
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85083834560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083834560&partnerID=8YFLogxK
U2 - 10.1007/s13167-020-00203-4
DO - 10.1007/s13167-020-00203-4
M3 - Review article
AN - SCOPUS:85083834560
SN - 1878-5077
VL - 11
SP - 217
EP - 250
JO - EPMA Journal
JF - EPMA Journal
IS - 2
ER -